Table 4.

Baseline characteristics and clinical outcome of patients who received allo-HCT transplantation after blinatumomab (N = 85)

	Value
Age, median (range), y	59 (18-72)
Median number or prior therapies (range)	2 (2-6)
Prior allo-HCT	5 (6)
Time from remission to allo-HCT, median (range), mo	1.7 (0.2-13.2)
Type of allo-HCT
Matched related donor	31 (37)
Matched unrelated donor	36 (42)
Haploidentical	13 (15)
Cord blood	5 (6)
Complication after allo-HCT
aGVHD	28 (33)
cGVHD	14 (16.5)
Veno-occlusive disease	2 (2)
Infectious complication	12 (14)
Transplant-related mortality in 100 d	6 (7)
Progression-free survival	NR (66% progression free at 2 y)
Overall survival	NR (62% alive at 2 y)

Values are n (%) unless otherwise noted.